When was Spero Therapeutics founded?

Spero Therapeutics was founded in 2013 and raised its 1st funding round within a year of its incorporation.

Where is Spero Therapeutics located?

Spero Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

Who is the current CEO of Spero Therapeutics?

Ankit Mahadevia of Spero Therapeutics.

How many employees does Spero Therapeutics have?

As of Mar 01, 2026, the latest employee count at Spero Therapeutics is 10 - 49.

Is Spero Therapeutics a funded company?

Spero Therapeutics is a funded company, having raised a total of $115M across 13 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 2013.

When was the latest funding round of Spero Therapeutics?

Spero Therapeutics' latest funding was a $***** Post IPO round on Nov 14, 2022, with participation from 0 investor.

What is the annual revenue of Spero Therapeutics?

Annual revenue of Spero Therapeutics is between $50M and $100M as on Dec 31, 2025

Where does Spero Therapeutics rank among its competitors?

Spero Therapeutics ranks 1st amongst 210 active competitors, of which 76 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was LimmaTech Biologics, which secured $2.2M in Feb, 2024.

Who are the top competitors of Spero Therapeutics?

Spero Therapeutics' top competitors include Vedanta Biosciences, Locus Biosciences and LimmaTech Biologics. Among them, LimmaTech Biologics secured the most recent funding round in February, 2024.

Spero Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Spero Therapeutics is a public company based in Cambridge (United States), founded in 2013 by Ankit Mahadevia. It operates as a Developer of therapeutics for drug-resistant bacterial infections. Spero Therapeutics has raised $115M in funding from investors like Atlas Venture, Partners Health Care Innovation and SR One. The company has 210 active competitors, including 76 funded and 40 that have exited. Its top competitors include companies like Vedanta Biosciences, Locus Biosciences and LimmaTech Biologics.

Company Details

Developer of therapeutics for drug-resistant bacterial infections. It offers a portfolio of novel product candidates which includes Tebipenem HBr, an oral carbapenem for pediatric infections, SPR720, an oral antimicrobial agent for the treatment of non-tuberculous mycobacterial lung disease, and SPR206, an intravenous (IV)-administered next-generation polymyxin analog for gram-negative bacterial infections.

Website: www.sperotherapeutics.com/
Social
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2013

Location

Cambridge, United States

Stage

Public

Total Funding

$115M in 13 rounds

Latest Funding Round

Post IPO, Nov 14, 2022, $*****

Investors

Atlas Venture & 17 more

Ranked

1^st among 210 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2025

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Vedanta Biosciences & 262 more

Exit Details

Public

View Spero Therapeutics' full profile

Spero Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Spero Therapeutics, Inc. CIN: 464590683 , United States, Active	Dec 31, 2012	$50M - $100M (As on Dec 31, 2025)	27 (As on Dec 31, 2024)	-
Spero Therapeutics, Inc. CIN: 20181300821 , United States, Active	Apr 10, 2018	-	-	-

Spero Therapeutics got listed on Nov 02, 2017.

Click here to take a look at Spero Therapeutics's IPO in detail

Spero Therapeutics has raised a total funding of $115M over 13 rounds. Its first funding round was on Apr 2013. Spero Therapeutics has 18 institutional investors.

Here is the list of recent funding rounds of Spero Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 14, 2022	9541420	Post IPO	8073979	8314235	3646421	7587350
Jan 19, 2022	8164176	Grant (prize money)	3385081	8817754	4954474	Medical Countermeasures
Jun 30, 2021	7125414	Post IPO	8341753	2236641	7229692	Pfizer

Access funding benchmarks and valuations. Sign up today!

View details of Spero Therapeutics's funding rounds and investors

The founders of Spero Therapeutics is Ankit Mahadevia.

Here are the details of Spero Therapeutics' key team members:

Ankit Mahadevia: Co-Founder & CEO of Spero Therapeutics and founder of 1 other company.

View details of Spero Therapeutics's Founder profiles and Board Members

Spero Therapeutics' employee count trend

Spero Therapeutics has 10 - 49 employees as of Mar 26. Here is Spero Therapeutics's employee count trend over the years:

Employee count trend for Spero Therapeutics

Uncover Spero Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Spero Therapeutics include Vedanta Biosciences, Locus Biosciences and LimmaTech Biologics. Here is the list of Top 10 competitors of Spero Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Spero Therapeutics 2013, Cambridge (United States), Public	Developer of therapeutics for drug-resistant bacterial infections	$115M	Lundbeck Foundation, Google Ventures & 16 others	69/100
2nd	Vedanta Biosciences 2010, Cambridge (United States), Series E	Developer of therapeutics to treat infectious diseases	$350M	Invesco, Seventure Partners & 38 others	65/100
3rd	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	64/100
4th	LimmaTech Biologics 2015, Schlieren (Switzerland), Acquired	Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques	$40M	REPAIR Impact Fund, Adjuvant Capital & 4 others	63/100
5th	Melinta Therapeutics 2000, Morristown (United States), Acquired	Developer of therapeutics for antibiotic-resistant infections	$186M	Warburg Pincus, SR One & 16 others	61/100
6th	Paratek Pharma 1996, Boston (United States), Acquired	Developer of therapeutics for antimicrobial resistant infections	$96.5M	HBM Healthcare Investments, Phase4 Partners ... & 25 others	61/100
7th	Everest Medicines 2017, New York City (United States), Public	Developer of drugs for the treatment of cancer	$313M	HBM Healthcare Investments, RA Capital Management ... & 12 others	61/100
8th	Bioversys 2008, Basel (Switzerland), Public	Developer of therapeutics for Antimicrobial Resistance	$62.5M	AMR Action Fund, Wellcome Trust & 10 others	61/100
9th	MicuRx Pharmaceuticals 2007, Foster City (United States), Series E	Develops antibiotics against multidrug-resistant (MDR) superbug infections	$272M	Legend Capital, BioVeda China Fund & 9 others	60/100
10th	UTILITY therapeutics 2017, Altrincham (United Kingdom), Acquired	Developer of antibiotics to treat urinary tract infections and multi-drug resistant infections	$2.52M	Dacco Invest, Adam Invest & 8 others	58/100